Bank of New York Mellon Corp Reduces Stock Position in Ascendis Pharma A/S $ASNDMarket Beat·Jul 24 at 02:26 AMASND-0.39%
Barometer Capital Management Inc. Reduces Holdings in Ascendis Pharma A/S $ASNDMarket Beat·Jul 22 at 03:09 AMASND-0.39%UBS+3.07%
Ascendis Pharma (ASND) Could Be 14% Below Fair Value As Growth Hopes HoldSimplywall·Jul 21 at 04:04 AMASND-0.39%
Marks Group Wealth Management Inc Purchases New Shares in Ascendis Pharma A/S $ASNDMarket Beat·Jul 17 at 04:37 AMASND-0.39%
Ascendis Pharma A/S (NASDAQ:ASND) Given Consensus Rating of "Buy" by AnalystsMarket Beat·Jul 13 at 03:44 AMASND-0.39%
Ascendis Pharma (ASND) Says 104 Week TransCon CNP Data Still Looks StrongSimplywall·Jul 12 at 12:23 AMASND-0.39%
Ascendis Pharma releases Week 104 ApproaCH trial radiographic data presentation on TransCon CNP in achondroplasiaPUBT·Jul 8 at 07:25 PMASND-0.39%
Ascendis Pharma (ASND) Could Be 7% Undervalued Following Fresh ApproaCH Trial DataSimplywall·Jul 3 at 06:53 PMASND-0.39%
Ascendis says TransCon CNP achondroplasia trial shows continued leg-alignment gains at Week 104PUBT·Jun 30 at 07:32 AMASND-0.39%
Ascendis Pharma added to Russell 3000, Russell 1000 and other US indexesMSN·Jun 26 at 04:05 PMASND-0.39%
Ascendis Pharma reports Week 104 ApproaCH trial data showing improved leg alignment with TransCon CNP in achondroplasiaPUBT·Jun 25 at 03:01 PMASND-0.39%
Ascendis Pharma sells priority review voucher for $187.5 million cashPUBT·Jun 17 at 03:48 PMASND-0.39%
